Hospices Civils de Lyon: Carcinoma trials

The registry lists 17 Carcinoma studies with Hospices Civils de Lyon as lead sponsor. 2 are open to participants now and 0 have results posted.

Phase 1 1Phase 2 2No phase 15(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Multicentric Evaluation of COVID-19 Impact on Cancer Patients' Diagnostic and Management: Set-up of IndicatorsRecruitingNCT05932719
• PITCHER (Peritoneal Carcinomatosis Heterogeneity)RecruitingNCT04714957
• Low Grade Serous Ovarian Carcinoma and Uterine Involvement : Should Hysterectomy be the RuleCompletedNCT05741554
• Fluoropyrimidine Tailored-dose Based on Uracil Concentration in Patients Treated for Digestive Carcinomas: Evaluation of Clinical PracticeCompletedNCT04918264
• Transarterial Chemoembolization Plus Hypofractionnated Radiotherapy vs. Surgery in Locally Advanced Hepatocellular Carcinoma: an IPTW ComparisonCompletedNCT04823715
• Radio/Pathological Evaluation of Tongue Cancer InfiltrationStatus unknownNCT04821128
• Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Peritoneal Carcinomatosis From Ovarian Cancer (Cyto-chip 2)CompletedNCT03931304
• Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Peritoneal Carcinomatosis From Gastric CancerCompletedNCT03253939
• Direct-acting Antivirals and Hepatocellular Carcinoma RecurrenceCompletedNCT03197155
• Perioperative Chemotherapy With Bevacizumab for Colorectal Carcinomatosis French Part of the Main Bev-IP StudyWithdrawnNCT03161041Phase 2
• Interest of MRI in Preoperative Staging for the Laryngeal and Hypopharyngeal CancerCompletedNCT03132727
• Safety of Intraperitoneal (IP) OXAliplatin (OXA) in Association With Systemic FOLFIRI Bevacizumab Chemotherapy in Patients With Peritoneal CarcinosisStatus unknownNCT02866903Phase 1/2
• Study Comparing the Role of the Laparoscopy Surgical Staging in the Peritoneal Carcinomatosis to Laparotomic ApproachStatus unknownNCT02829788
• Liver Perfusion MRI With Quantification of Tumoral Perfusion for Early Assessment of the Response of Antiangiogenics Treatments in Hepatocellular CarcinomaTerminatedNCT02585687Not applicable
• Determination of Pronostics Factors for Advanced Thyroid Carcinoma (pT3 pT4 or M1 at Diagnosis)Status unknownNCT02156362Not applicable
• Diagnostic Performance of 18F-FDG-PET and Diffusion-weighted MRI in the Assessment of Stage IB to IIB2 Cervical Squamous-cell Carcinoma Response to Concomitant Radiochemotherapy and BrachytherapyCompletedNCT01663753Not applicable
• Representation of the Body for Patients With CancerCompletedNCT01560533Not applicable